Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: A 12-year follow-up in two cohorts

Vaccine

Volumn 16, Issue 20, 1998, Pages 2052-2057

  Davidkin, Irja ^a   Valle, Martti ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Antibody kinetics; Measles antibodies; Two dose MMR vaccination

Indexed keywords

MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHILD; FINLAND; FOLLOW UP; HEMAGGLUTINATION INHIBITION TEST; HUMAN; MAJOR CLINICAL STUDY; MEASLES; MEASLES VACCINATION; MUMPS; PRIORITY JOURNAL; RUBELLA; SEROCONVERSION; VIRUS NEUTRALIZATION; VIRUS PLAQUE;

ANTIBODIES, VIRAL; COHORT STUDIES; FEMALE; FINLAND; FOLLOW-UP STUDIES; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOENZYME TECHNIQUES; INFANT; MALE; MEASLES VACCINE; MEASLES VIRUS; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS VACCINE; NEUTRALIZATION TESTS; RUBELLA VACCINE; VACCINES, COMBINED;

EID: 0032400613     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00081-4     Document Type: Article

References (29)

1. 1 Peltola, H. et al. Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland. Lancet 1986, 2, 137-139.
2. 2 Paunio, M. et al. Increase in vaccination coverage by mass media and individual approach: intensified measles, mumps, and rubella prevention program in Finland. Am. J. Epidemiol. 1991, 133, 1152-1160.
3. 3 Peltola, H., Heinonen, O.P., Valle, M., Paunio, M., Virtanen, M., Karanko, V. and Cantell, K. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two dose vaccination program. N. Engl. J. Med. 1994, 331, 1397-1402.
4. 4 Muller, C.P., Huiss, S. and Schneider, F. Secondary immune responses in parents of children with recent measles. Lancet 1996, 348, 1379-1380.
5. 5 Miller, C. Live measles vaccine: a 21 year follow up. Br. Med. J. 1987, 295, 22-24.
6. 6 Ramsay, M.E.B., Moffat, D. and O'Connor, M. Measles vaccine: a 27-year follow-up. Epidemiol. Infect. 1994, 112, 409-412.
7. 7 Markowitz, L.E, Preblud, S.R., Fine, P.E.M. and Orenstein, W.A. Duration of live measles vaccine-induced immunity. Pediatr. Infect. Dis. J. 1990, 9, 101-110.
8. 8 Pedersen, I.R., Mordhorst, C.H., Ewald, T. and von Magnus, H. Long-term antibody response after measles vaccination in an isolated arctic society in Greenland. Vaccine 1986, 4, 173-178.
9. 9 Bin, D. et al. Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province. China. Bull. WHO 1991, 69, 415-423.
10. 10 Krugman, S. Further-attenuated measles vaccine: characteristics and use. Rev. Infect Dis. 1983, 5, 477-481.
11. 11 Gershon, A.A. and Krugman, S. Measles virus. In: Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections, 5th edn (Eds Lennette, E.H. and Schmidt, N.J.). American Public Health Association, Washington, DC, 1979, pp. 685-686.
12. 12 Christenson, B. and Böttiger, M. Methods for screening the naturally acquired and vaccine-induced immunity to the measles virus. Biologicals 1990, 18, 207-211.
13. 13 Orenstein, A.W., Albrecht, P., Herrmann, K.L., Bernier, R., Bart, K.J. and Rovira, E.Z. The plaque-neutralization test as a measure of prior exposure to measles virus. J. Inf. Dis. 1987, 155, 146-149.
14. 14 Ratnam, S., Gadag, V., West, R., Burris, J., Oates, E., Stead, F. and Bouilianne, N. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J. Clin. Microbiol. 1995, 33, 811-815.
15. 15 Sakata, H. and Sugiura, A. Passive hemagglutination test for measles immunity and serodiagnosis. J. Clin. Microbiol. 1988, 26, 636-640.
16. 16 Weigle, K.A., Murphym, M.D. and Brunell, P.A. Enzyme-linked immunoabsorbent assay for evaluation of immunity to measles virus. J. Clin. Microbiol. 1984, 19, 376-379.
17. 17 Guris, D. et al. Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. Pediatr. Infect. Dis. J. 1996, 15, 1082-1086.
18. 18 Brown, P., Gadjusek, D.C. and Tsai, T. Persistence of measles antibody in the absence of circulating natural virus five years after immunization of an isolated virgin population with Edmonston B vaccine. Am. J. Epidemiol. 1969, 90, 514-518.
19. 19 Miller, E., Hill, A., Morgan-Capner, P., Forsey, T. and Rush, M. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine 1995, 13, 799-802.
20. 20 Boulianne, N., De Serres, G., Ratnam, S., Ward, B.J., Joly, J.R. and Duval, B. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination. Vaccine 1995, 13, 1611-1616.
21. 21 Ward, B.J., Boulianne, N., Ratnam, S., Guiot, M.-C., Couillard, M. and De Serres, G. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J. Inf. Dis. 1995, 172, 1591-1595.
22. 22 Zhang, Y. and Su, W. Introduction to the control of measles by vaccination in the People's Republic of China. Rev. Inf. Dis. 1983, 5, 568-573.
23. 23 Markowitz, L.E., Albrecht, P., Orenstein, W.A., Lett, S.M., Pugliese, T.J. and Farrell, D. Persistence of measles antibody after revaccination. J. Infect. Dis. 1992, 166, 205-208.
24. 24 Böttiger, M. Boosting effect of a second dose of measles vaccine given to 12-year-old children. Scand. J. Infect. Dis. 1993, 25, 239-243.
25. 25 Bass, J.W. et al. Booster vaccination with further live attenuated measles vaccine. JAMA 1976, 235, 31-34.
26. 26 Albrecht, P., Herrmann, K. and Burns, G.R. Role of virus strain in conventional and enhanced measles plaque neutralization test. J. Virol. Methods. 1981, 3, 251-260.
27. 27 WHO. Immunization Policy. Global Programme for Vaccines and Immunization, Expanded Programme on Immunization, WHO, Geneva, 1995.
28. 28 Chen, R.T., Markowitz, LE., Albrecht, P., Stewart, J.A., Mofeson, L.M., Preblud, S.R. and Orenstein, W.A. Measles antibody: reevaluation of protective titers. J. Infect. Dis. 1990, 162, 1036-1042.
29. 29 Peltola, H., Davidkin, I., Valle, M., Paunio, M., Hovi, T., Heinonen, O.P. and Leinikki, P. No measles in Finland. Lancet 1997, 350, 1364-1365.